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A B S T R A C T
Plasmodium falciparum and P. vivax co-exist at diﬀerent endemicity levels across Ethiopia. For over two decades
Artemether-Lumefantrine (AL) is the ﬁrst line treatment for uncomplicated P. falciparum, while chloroquine (CQ)
is still used to treat P. vivax. It is currently unclear whether a shift from CQ to AL for P. falciparum treatment has
implications for AL eﬃcacy and results in a reversal of mutations in genes associated to CQ resistance, given the
high co-endemicity of the two species and the continued availability of CQ for the treatment of P. vivax. This
study thus assessed the prevalence of Pfcrt-K76T and Pfmdr1-N86Y point mutations in P. falciparum. 18S RNA
gene based nested PCR conﬁrmed P. falciparum samples (N=183) collected through community and health
facility targeted cross-sectional surveys from settings with varying P. vivax and P. falciparum endemicity were
used. The proportion of Plasmodium infections that were P. vivax was 62.2% in Adama, 41.4% in Babile, 30.0% in
Benishangul-Gumuz to 6.9% in Gambella. The Pfcrt-76T mutant haplotype was observed more from samples
with higher endemicity of P. vivax as being 98.4% (61/62), 100% (31/31), 65.2% (15/23) and 41.5% (22/53) in
samples from Adama, Babile, Benishangul-Gumuz and Gambella, respectively. However, a relatively higher
proportion of Pfmdr1-N86 allele (77.3–100%) were maintained in all sites. The observed high level of the mutant
Pfcrt-76T allele in P. vivax co-endemic sites might require that utilization of CQ needs to be re-evaluated in
settings co-endemic for the two species. A country-wide assessment is recommended to clarify the implication of
the observed level of variation in drug resistance markers on the eﬃcacy of AL-based treatment against un-
complicated P. falciparum malaria.
1. Introduction
Development and spread of anti-malaria drug resistance continued
to be a stumbling-block in the ﬁght against malaria. Plasmodium falci-
parum developed resistance to most of the antimalarials over the past 60
years (White, 2004). Resistance against Artemisinin combination
therapies (ACT) (Carrara et al., 2013; Dondorp et al., 2009; Leang et al.,
2013) is reported in Thai-Cambodian border, a historical ‘hotspot’ for
multi-drug resistance parasite evolution, emergence and spread. Al-
though ACTs retain high eﬃcacy in sub-Saharan African countries in-
cluding Ethiopia (Barnes et al., 2009; Taﬀese et al., 2018), recent re-
ports are suggestive of the emergence of ACT tolerant P. falciparum in
African settings (Xu et al., 2018).
One of the mechanisms for emergence of drug resistance in
Plasmodium is acquisition of mutations and duplication in target and/or
transporter genes. Artemether-Lumefantrine (AL) selects for wild-type
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codons at the P. falciparum chloroquine resistance transporter (Pfcrt-
K76) and P. falciparum multidrug resistance 1 (Pfmdr1) alleles
(Baliraine and Rosenthal, 2011; Sisowath et al., 2005) and its use is
associated with increases in Pfmdr1 gene copy number (Price et al.,
2004). Variations were reported on the selective eﬀects of diﬀerent
ACTs on single-nucleotide polymorphisms in Pfcrt and Pfmdr1. A recent
systemic review of 397 surveys in 30 countries in Africa documented
that AL and artesunate-amodiaquine (ASAQ) exert opposing selective
pressures and parasites under the selection pressure of one ACT tend to
be more sensitive to the other (Okell et al., 2018). Higher proportion of
Pfmdr1-86N and increases in its copy number have been reported in AL
treated patients with parasite recrudescence (Venkatesan et al., 2014).
It was noted that ASAQ selects the Pfmdr1 mutant haplotypes, 86Y,
Y184, and 1246Y (Venkatesan et al., 2014). Chloroquine is known to
select the mutant Pfcrt-K76T and the wild type Pfmdr1-N86Y haplotypes
(Gbotosho et al., 2012). Therefore, in areas where both P. falciparum
and P. vivax are co-endemic the continued use of CQ might result in
pronounced diﬀerent selective pressure and, as a consequence, diﬀerent
drug resistance proﬁles in communities.
Unlike most of Africa, P. falciparum (60%) co-exists with P. vivax
(40%) in most settings in Ethiopia. Driven by the widespread CQ re-
sistant P. falciparum, Ethiopia changed its treatment policy for P. fal-
ciparum from CQ to sulphadoxine-pyrimethamine (SP) in 1998 (Jima
et al., 2005; Taﬀese et al., 2018); shortly after SP was replaced by AL as
ﬁrst-line therapy for uncomplicated falciparum malaria in 2004 (MOH,
2018; Taﬀese et al., 2018). Throughout this period, CQ continued to be
used as ﬁrst line treatment for P. vivax (MOH, 2018). This may have
implications for selection of drug resistance marker genes. Here, we
examined the prevalence of Pfcrt-K76T and Pfmdr1-N86Y alleles in P.
falciparum after two decades of AL implementation as ﬁrst line treat-
ment in areas with diﬀerent P. vivax co-endemicity levels in Ethiopia.
2. Materials and methods
2.1. Study sites and samples
Study sites were selected based on reported diﬀerence in P. vivax
and P. falciparum co-endemicity levels (Ministry of Health, 2016). Six
Woredas (districts) representing diﬀerent epidemiological settings from
three regional administrative states (Gambella, Benishangul-Gumuz
and Oromia) were included. Gambella region, with Abobo and Lare
districts, is a P. falciparum dominated area (97% of all Plasmodium in-
fections are P. falciparum) (Tsegaye et al., 2014) with perennial trans-
mission. Benishangul-Gumuz region, with Mao-Komo and Menge dis-
tricts, is also P. falciparum dominated with relatively higher prevalence
of P. vivax (10.1%) (Geleta and Ketema, 2016) and more seasonal
transmission. The Oromia region study site districts of Babile and
Adama are characterized by seasonal malaria transmission with co-
endemicity for P. falciparum and P. vivax where P. vivax infections at-
tributed to be 41.4% (Keﬀale et al., 2019) in the ﬁrst and 62.2%
(Tadesse et al., 2018) in the later district, respectively (Fig. 1 and
Table 1). Oromia regional state has wider variation in the P. vivax and
P. falciparum infection proportions due to its huge landmass and sam-
pling was done in separate years i.e. Adama in 2016 and Babile in 2017,
hence we have made separate treatment of the data from the study sites.
Study participants were recruited in community and health facility
based cross-sectional surveys. Community based cross-sectional surveys
were conducted in Babile district from July to November 2017 and from
October to December 2016 in all other sites. In Adama passively-de-
tected clinical malaria infected patients (n=36) were recruited in
addition to the community survey samples (n=33). Finger prick blood
samples (~300 μL) were collected from the study participants for ma-
laria diagnosis using rapid diagnostic test (RDT) (First Response
Malaria Ag (pLDH/HRP2, Combo RDT, Premier Medical Corporation
Ltd., India) or microscopy and to prepare dried blood spots (DBS) on
Whatman 3MM ﬁlter paper (Whatman, Maidstone, UK). Socio-
demographic and malariometric data were captured using pre-tested
structured questionnaire.
2.2. Detection of Pfcrt and Pfmdr1 polymorphisms
Study participants were diagnosed for malaria using thick blood
smears and thin smears were used for species identiﬁcation following
Giemsa-staining by two experienced microscopists who were in-
dependent and blind for the participants’ clinical status and RDT re-
sults. A third World health organization certiﬁed microscopist was
consulted in case of discordant results. Blood ﬁlm slides were con-
sidered negative if no parasite was detected after examining 100 mi-
croscopic ﬁelds (Tadesse et al., 2018).
Furthermore, DNA was extracted from a 6mm diameter punch of
DBS using Chelex-Saponin extraction method as described elsewhere
(Baidjoe et al., 2013); eluted DNA was stored at −20 °C until further
use. Malaria species was conﬁrmed with 18S based nested polymerase
chain reaction (nPCR) as described elsewhere (Snounou et al., 1993).
Samples that were conﬁrmed to be P. falciparum mon-species infection
using the 18S RNA nPCR (Snounou et al., 1993) were further ampliﬁed
for the Pfcrt-76 and Pfmdr1-86 genes using nPCR with outer (N1) and
inner primer pairs (N2) (Supplement 1). The N2 products were assessed
using restriction fragment length polymorphism (RFLP) to detect mu-
tations at each locus (Djimde et al., 2001; Veiga et al., 2006). Restric-
tion enzymes used and conditions of digestion were as described else-
where (UMSM, 2012). For Pfcrt-76 codon, a known positive control of
3D7 (wild-type, Pfcrt-76K allele) and negative control of Dd2 (mutant)
were included in each reaction (kindly provided by the Ethiopian Public
Health Institute). Restriction enzyme digested products were visualized
with UV transilluminator after electrophoresis using 2% Agarose gel
(SIGMA-ALDRICH) with a no enzyme digest control run alongside po-
sitive controls, negative controls and test samples (Bio Rad, USA).
Mixed haplotypes having both wild and mutant type were interpreted
as combined band patterns of digested and undigested products iden-
tiﬁed per sample of DNA.
2.3. Ethics statement
The study protocol was approved by the National Research Ethical
Review Committee (3.10|016\20), Institutional Ethical Review Board
of the College of Natural Science at Addis Ababa University, and AHRI/
ALERT (Ref.No.SOM/DRERC/BCH005/2009, PO24/17). Written in-
formed consent was obtained from each adult and parent/legal guar-
dians for children younger than 18 years. Symptomatic patients were
treated as per the national treatment guideline (MOH, 2018).
2.4. Statistical analysis
Both laboratory and ﬁeld data were double entered. The cleaned
data was analyzed using STATA 13 (StataCorp, TX, USA). The diﬀer-
ence in prevalence among study sites was compared using Fisher's exact
test. Pairwise comparison, after Bonferroni correction, was run to test
diﬀerences in distribution of the wild and mutant alleles between the
study sites for both Pfcrt-76 and Pfmdr1-86 codons. A P-value ≤ 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Characteristics of the study participants
A total of 183 samples from 148 asymptomatic and 35 symptomatic
participants with P. falciparum infection by 18S nPCR were included in
the study. Out of the 183 samples, 169 (92.3%) and 168 (91.8%) were
successfully ampliﬁed for Pfcrt-76 and Pfmdr1-86 codons, respectively.
Adama was the only site where asymptomatic and symptomatic study
participants were considered. There was no signiﬁcant diﬀerence
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among wild type and mutant haplotypes of the Pfcrt-76 codons between
the asymptomatic (7.4%, 2/27) and symptomatic (8.6%, 3/35;
P=0.125) samples of Adama hence considered together in the sub-
sequent analysis. Only wild type form of Pfmdr1-86 was detected in
both groups.
3.2. Prevalence of Pfcrt-76 haplotypes varies between study sites and P.
vivax co-endemicity
Overall, the wild type Pfcrt-K76 haplotype was detected in 23.7%
(40/169) and the mutant Pfcrt-76T in 76.3% (129/169) of samples
across sites. We observed a statistically signiﬁcant diﬀerence in the
prevalence of Pfcrt-76 codons among the study sites (P < 0.001):
mutant (Pfcrt-76T) type was virtually ﬁxed in Babile (100%, 31/31) and
with near ﬁxation at Adama (98.4%, 61/62) districts of Oromia region
where P. vivax is highly endemic (41.4% and 62.2% of cases, respec-
tively) (Keﬀale et al., 2019; Tadesse et al., 2018). On the other hand, a
higher prevalence of the wild type (Pfcrt-K76) codon was found in
Abobo and Lare districts of Gambella (58.5%, 31/53) and in Mao-Komo
and Menge districts of Benishangul-Gumuz (34.8%, 8/23) (Table 1).
The proportion of infections that is P. vivax is very low (< 10%) in
these settings (Geleta and Ketema, 2016; Tsegaye et al., 2014)
(Table 1). After Bonferroni correction, diﬀerences in the proportion of
Pfcrt-76T among the study sites was observed (P=0.0342).
3.3. High prevalence of Pfmdr1-86 wild haplotype across the study sites
The overall prevalence of the mutant codon, Pfmdr1-86Y, was 5.9%
(10/168). The wild type codon, Pfmdr1-N86, was found ﬁxed (100%) in
Babile and Adama districts with similar higher proportions in Abobo
and Lare districts of Gambella (90.4%, 47/52) and Mao-Komo and
Menge districts of Benishangul-Gumuz (77.3%, 17/22). The prevalence
of the mutant type (Pfmdr1-86Y) was only 9.6% (5/52) and 22.7% (5/
22) in the districts from Gambella and Benishangul-Gumuz, respec-
tively. Moreover, the observed prevalence of the diﬀerent haplotypes
was signiﬁcantly diﬀerent among the study sites (P=0.001) (Table 1).
No diﬀerence was observed in the proportion of Pfmdr1-N86 in be-
tween study sites after Bonferroni correction (P=1.0).
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Fig. 1. The prevalence of Pfcrt-76K/T and Pfmdr1-86N/Y point mutations among samples from four study sites with diﬀerent P. vivax co-endemicity level compared
to P falcipaum. Where; wild = wild type alleles Pfmdr 1-86N and Pfcrt-76K and Mutant=mutant type alleles Pfmdr1-86Y and Pfcrt -76T.
Table 1
Characteristics of study participants and frequency point mutations of P. falciparum chloroquine resistance transporter (Pfcrt-76) and multi drug resistance 1 (Pfmdr1-
86) genes among samples from four sites in Ethiopia from 2016 to 2017.
Characteristics Gambella
N=55e
Benishangul-Gumuz
N=26e
Babile
N=33e
Adama
N=69+
Total
N=183
P-value
Age (years), Median (IQR) 13(8–18) 12(9–18) 15(8–35) 20 (8–32) 14(8–25)
Female sex, n (%) 24(43.6) 11(42.0) 13(39.4) 27(39.1) 75(41.0)
Proportion of infections that are P. vivax, % 2.6 a 10.1 b 41.4 c 62.2 d
Ampliﬁed samples for Pfcrt-76 codon, n/N 53/55 23/26 31/33 62/69 169/183
Pfcrt-K76 (wild type), % (n/N) 58.5 (31/53) 34.8 (8/23) 0.0 (0/31) 1.6 (1/62) 23.7(40/169)
Pfcrt-76T (Mutant), % (n/N) 41.5 (22/53) 65.2 (15/23) 100.0(31/31) 98.4(61/62) 76.3(129/169) <0.001
Ampliﬁed samples for Pfmdr1-86 codon, n/N 52/55 22/26 32/33 62/69 168/183
Pfmdr1-N86 (wild type), % (n/N) 90.4(47/52) 77.3(17/22) 100.0(32/32) 100.0(62/62) 94.1(158/168)
Pfmdr1-86Y (Mutant), % (n/N) 9.6(5/52) 22.7(5/22) 0.0(0/32) 0.0(0/62) 5.9 (10/168) <0.001
IQR, interquartile range.
+asymptomatic cases (n = 33) & passively recruited clinical cases (n = 36).
a Tsegaye et al., Mal J 2014.
b Geleta and Ketema Malar Res Treat (2016).
c Keﬀale et al. TRSTMH 2019.
d Tadesse et al. CID 2019.
e Asymptomatic cases.
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4. Discussion
The return of wild type alleles of CQ resistance marker genes has
been reported across Africa following replacement of CQ by ACTs
(Baraka et al., 2018; Kavishe et al., 2014; Okell et al., 2018; Venkatesan
et al., 2014). The possible associations of these markers with ACT drug
tolerance underline the need for continued surveillance for the success
of malaria control program. In this study we assessed the prevalence of
Pfcrt-K76T and Pfmdr1-N86Y codons from diﬀerent P. falciparum and P.
vivax co-endemicity settings in Ethiopia.
The current study has documented a higher frequency of Pfcrt-76T
mutant haplotypes proportional to the endemicity level of P. vivax as
being 98.4%, 100%, 65.2% and 41.5% in samples from Adama, Babile,
Benishangul-Gumuz and Gambella, respectively. Lower proportion of
parasites with the mutant allele (Pfcrt-76T) was detected in samples
from Gambella and Benishangul-Gumuz where P. falciparum is the
dominant species. The nearly approaching ﬁxation of Pfcrt-76T mutant
haplotype in Adama and its ﬁxation in Babile districts of Oromia region
was in agreement with previous reports in Ethiopia (Golassa et al.,
2014; Mula et al., 2011). This might be partly due to the high pre-
valence of P. vivax co-endemicity that probably lead to the continued
utilization and easy access of CQ in these areas. Similar ﬁndings asso-
ciating resistance markers with CQ use have been reported elsewhere:
persisting high levels of mutant Pfcrt haplotypes in infections from
Brazil and, in contrast, the reappearance of wild type forms in Nigeria
have been attributed to diﬀerences in the selective pressure by CQ use
(Gbotosho et al., 2012). Moreover, the slow reappearance of CQ sen-
sitive parasites harboring Pfcrt-K76 haplotype in low P. vivax pre-
valence areas of Gambella and Benishangul-Gumuz corroborates ob-
servations from other African countries such as Malawi (Kublin et al.,
2003), Côte d’Ivoire (Dagnogo et al., 2018), Zambia (Mwanza et al.,
2016),Tanzania (Mohammed et al., 2013) and Kenya (Achieng et al.,
2015).
Higher proportion of the wild type allele, Pfmdr1-N86,
(77.3–100%), was detected in all sites; ﬁxed in Babile and Adama. This
ﬁnding was in line with previous reports from diﬀerent parts of
Ethiopia (Lo et al., 2017; Mekonnen et al., 2014a; Mula et al., 2011).
Earlier studies conducted more than a decade ago indicated a non-
negligible level of the mutant form in Ethiopia (Eshetu et al., 2010;
Schunk et al., 2006). This is probably due to the AL-regimen rolled out
as ﬁrst line treatment for P. falciparum infection across the study sites.
In African settings, after decades of AL use a rise in the “NFD” Pfmdr1
haplotypes at codons-86,184 and 1246 have been observed with a
parallel decline in the “YYY” haplotypes of these codons (Duah et al.,
2013; Okell et al., 2018; Sondo et al., 2016; Venkatesan et al., 2014).
These studies found that the “NFD” haplotypes were associated with the
reduced sensitivity of the parasite to AL treatment.
The observed diﬀerence across the study sites is plausibly associated
with antimalarial drug pressure as observed in other co-endemic set-
tings. The re-emergence of genotypes such as Pfcrt-K76 and Pfmdr-1
codons-N86, 184F and D1246 after CQ withdrawal has been associated
with selection of parasites with reduced sensitivity to AL (Achieng
et al., 2015; Conrad et al., 2014; Dokomajilar et al., 2006; Sisowath
et al., 2009) which may eventually lead to resistance (Ljolje et al., 2018;
Sisowath et al., 2005; Venkatesan et al., 2014). Moreover, in settings
where P. falciparum and P. vivax are sympatric where mixed species
infections are common, the detection of P. falciparum is frequent fol-
lowing treatment of P. vivax with CQ (Heuchert et al., 2015; Mekonnen
et al., 2014b; Tajebe et al., 2014). Thus, the low CQ level to which the
P. falciparum will be exposed might favor selective pressure. .
The strength of this study is that it considered samples from dif-
ferent levels of P. vivax and P. falciparum co-endemicity (with varied CQ
pressure) and both symptomatic and asymptomatic individuals. It is less
likely to have a shift in proportion of infections due to P. vivax in the
two years of sampling (20016 and 2017); the over decade national
malaria control program data summary (2001–2016), documented no
considerable change in the proportion of infections due to P. vivax in
Ethiopia (Taﬀese et al., 2018). The almost complete reversal of the wild
haplotype, Pfmdr1-N86 codon, in all our sites reinforce the claim that
such phenomenon might be due to ACT based treatment. Thus, we
suggest parallel surveillance of drug resistance markers to monitor the
eﬀects of the antimalarial-drugs deployed in areas where P. vivax and P.
falciparum are co-endemic. The similarity in the drug resistance proﬁle
among asymptomatic individuals and clinical patients is suggestive of
asymptomatic infections could serve as hidden reservoirs. Therefore,
our ﬁnding also underpin the importance of involving asymptomatic
reservoirs in the evaluation of drug resistance especially in areas ap-
proaching elimination (Nyunt et al., 2017).
This study would have been more comprehensive if clonality of
infections and copy number variations (CNVs) of target genes were
assessed. We reported mixed haplotypes for Pfcrt-76 (8.0%, 13/169)
and Pfmdr1-86 (4.2%, 7/168). As the study was based on PCR-RFLP
method alone ascertaining whether any of the two haplotypes were
coming from the same genome or multi-clonal infections was diﬃcult;
hence we reported the mixed haplotypes together with the mutant
proportions. Also, Pfmdr1-86 CNV is implicated for the emergence of P.
falciparum diminished susceptibility to anti-malarial drugs, such as
meﬂoquine, AS-MQ and AL combinations (Duah et al., 2013;
Venkatesan et al., 2014).
In conclusion, after two decades of the replacement of CQ with AL
for the treatment of uncomplicated falciparum malaria in Ethiopia,
there is slow but site-speciﬁc reversal of the Pfcrt-K76 haplotype while
the Pfmdr1-N86 wild type was almost ﬁxed across study sites, a pre-
liminary ﬁnding that calls the need for monitoring and responding to
emerging signs of drug resistance to preserve the eﬃcacy of anti-
malarial drugs. Thus, we recommend country-wide assessments to
clarify the implication of the observed level of variation in drug re-
sistance markers on the eﬃcacy of AL-based treatment against un-
complicated P. falciparum malaria.
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